Comparative In Vitro Activities of Meropenem in Combination with Colistin, Levofloxacin, or Chloramphenicol Against Achromobacter xylosoxidans Strains Isolated from Patients with Cystic Fibrosis.
暂无分享,去创建一个
[1] F. Compain,et al. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. , 2018, Journal of medical microbiology.
[2] N. nørskov-lauritsen,et al. Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. , 2017, Journal of medical microbiology.
[3] E. R. Rodrigues,et al. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis , 2016, Epidemiology and Infection.
[4] S. Verhulst,et al. Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease , 2016, The American journal of case reports.
[5] J. Turton,et al. Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[6] A. Peleg,et al. Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies , 2015, Seminars in Respiratory and Critical Care Medicine.
[7] M. Landini,et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. , 2014, The Journal of antimicrobial chemotherapy.
[8] M. Skov,et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[9] P. Vandamme,et al. Identification and distribution of Achromobacter species in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[10] J. Elborn,et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[11] S. Mishra,et al. Miscellaneous Gram‐Negative Bacteria , 2012 .
[12] M. Gonullu,et al. Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans , 2012, Scandinavian journal of infectious diseases.
[13] M. Almuzara,et al. Achromobacter xylosoxidans: An Emerging Pathogen Carrying Different Elements Involved in Horizontal Genetic Transfer , 2012, Current Microbiology.
[14] R. Albano,et al. Achromobacter xylosoxidans: Characterization of Strains in Brazilian Cystic Fibrosis Patients , 2011, Journal of Clinical Microbiology.
[15] V. Raia,et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients , 2011, European Journal of Clinical Microbiology & Infectious Diseases.
[16] B. Özbek,et al. Postantibiotic Effects of Tigecycline, Colistin Sulfate, and Levofloxacin Alone or Tigecycline-Colistin Sulfate and Tigecycline-Levofloxacin Combinations against Acinetobacter baumannii , 2010, Chemotherapy.
[17] G. Drusano,et al. The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression , 2010, Antimicrobial Agents and Chemotherapy.
[18] M. Almuzara,et al. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. , 2010, International journal of antimicrobial agents.
[19] S. Leonardi,et al. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients , 2009, European Journal of Clinical Microbiology & Infectious Diseases.
[20] M. Vaneechoutte,et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[21] Ronald N. Jones,et al. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. , 2005, International journal of antimicrobial agents.
[22] R. Gibson,et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[23] Tim Tolker-Nielsen,et al. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. , 2003, Current opinion in biotechnology.
[24] L. Saiman,et al. Identification and Antimicrobial Susceptibility ofAlcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis , 2001, Journal of Clinical Microbiology.
[25] D. Nix,et al. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. , 2001, Diagnostic microbiology and infectious disease.
[26] C. Chenoweth,et al. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] K. Rolston,et al. The in-vitro susceptibility of Alcatigenes deni-trificans subsp.xylosoxidans to40 anti-microbial agents , 1990 .
[28] R. Dessau,et al. Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. , 1988, The Journal of hospital infection.
[29] J. Klastersky,et al. Synergistic combinations of antibiotics in gram-negative bacillary infections. , 1982, Reviews of infectious diseases.
[30] W Satterlee,et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. , 1971, The New England journal of medicine.